BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35941008)

  • 1. Biochemical relapse predictive factors in patients with lymph node metastases during radical prostatectomy.
    Mandoorah Q; Benamran D; Pinar U; Seisen T; Abdessater M; Iselin C; Rouprêt M
    Prog Urol; 2022 Dec; 32(16):1462-1468. PubMed ID: 35941008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.
    Kim DK; Koo KC; Abdel Raheem A; Kim KH; Chung BH; Choi YD; Rha KH
    PLoS One; 2016; 11(3):e0152391. PubMed ID: 27031340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
    Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
    Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
    Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
    BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
    Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
    Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer.
    Morizane S; Honda M; Shimizu R; Teraoka S; Nishikawa R; Tsounapi P; Kimura Y; Iwamoto H; Hikita K; Takenaka A
    Int J Clin Oncol; 2020 Jul; 25(7):1398-1404. PubMed ID: 32333202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of biochemical recurrence after radical prostatectomy in an Afro-Caribbean population in Guadeloupe (French West Indies).
    Brureau L; Emeville E; Multigner L; Blanchet P
    Prog Urol; 2018 Jun; 28(8-9):442-449. PubMed ID: 29789237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mid-term oncologic outcomes of radical prostatectomy in lymph node metastatic prostate cancer patients.
    Berchiche W; Long Depaquit T; Baboudjian M; Barret É; Rozet F; Cathelineau X; Bastide C
    Prog Urol; 2023 Aug; 33(8-9):437-445. PubMed ID: 37248105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients.
    Schiavina R; Bertaccini A; Franceschelli A; Manferrari F; Vagnoni V; Borghesi M; Morselli-Labate AM; Martorana G
    Anticancer Res; 2010 Jun; 30(6):2297-302. PubMed ID: 20651383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
    Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
    Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
    Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?
    Kluth LA; Xylinas E; Rieken M; Chun FK; Fajkovic H; Becker A; Karakiewicz PI; Passoni N; Herman M; Lotan Y; Seitz C; Schramek P; Remzi M; Loidl W; Guillonneau B; Rouprêt M; Briganti A; Scherr DS; Graefen M; Tewari AK; Shariat SF
    Urol Oncol; 2014 Jan; 32(1):47.e1-8. PubMed ID: 24055425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy.
    Pagano MJ; Whalen MJ; Paulucci DJ; Reddy BN; Matulay JT; Rothberg M; Scarberry K; Patel T; Shapiro EY; RoyChoudhury A; McKiernan J; Benson MC; Badani KK
    Prostate; 2016 Feb; 76(2):226-34. PubMed ID: 26481325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
    Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
    Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
    Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.